<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868137</url>
  </required_header>
  <id_info>
    <org_study_id>1335793-1</org_study_id>
    <nct_id>NCT03868137</nct_id>
  </id_info>
  <brief_title>Multi-dose Ibuprofen Prophylaxis for IUD-insertion</brief_title>
  <acronym>MIPI</acronym>
  <official_title>Multi-dose Ibuprofen Prophylaxis for IUD-insertion (MIPI): A Triple Blinded</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orlando VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orlando VA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effectiveness of decreasing pain at time of and day after
      intrauterine device (IUD) insertion when patients take three doses of Ibuprofen versus three
      doses of placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ibuprofen is commonly used over the counter and prescribed for pain relief such as menstrual
      cramps. Intrauterine (IUD) insertion can cause pain during and after the insertion.
      Currently, studies have found that single dose of Ibuprofen take prior to IUD insertion does
      decrease pain at time of IUD insertion. This study will examine whether 3 doses of Ibuprofen
      can decrease pain at time of and 1 day after IUD insertion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Triple blind randomized control trial involving placebo arm and intervention arm (Ibuprofen)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A randomization sequence will be generated and given to the research pharmacist who will dispense the appropriate medications to the participants in each arm. Only the pharmacist will know which patient is in which trial arm until the study has ended and data has been analyzed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain at time of IUD insertion</measure>
    <time_frame>At time of IUD insertion</time_frame>
    <description>Pain score measured on 10 point visual analog scale (VAS): 0-3 mild pain, 4-7 moderate pain, 8-10 severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at 1 day after IUD insertion</measure>
    <time_frame>1 day after IUD insertion</time_frame>
    <description>Pain score measured on 10 point visual analog scale (VAS): 0-3 mild pain, 4-7 moderate pain, 8-10 severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of other medications or methods to decrease post-IUD insertion pain</measure>
    <time_frame>1 day after IUD insertion</time_frame>
    <description>Names of other medications or methods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Pelvic Pain</condition>
  <condition>IUD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>3 doses of Ibuprofen 800 mg</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 18

          -  Female

          -  Able to provide informed consent

          -  English speaking

          -  Able to provide telephone and address contact information

          -  Able and willing to receive HIPAA compliant telephone texts and phone messages

          -  Stable (the same) address and phone number within the last 6 months.

        Exclusion Criteria:

          -  Contraindications to IUD insertion (active pelvic infection, current pregnancy)

          -  Contraindications to NSAIDs (allergy, history of asthma, history of aspirin allergy,
             history of kidney disease, history of stomach ulcer, history of active GI bleeding,
             history of liver disease)

          -  Not undergoing any other concurrent office procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patient must be female since IUDs are female contraception.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chensi Ouyang, MD</last_name>
    <phone>407-631-1000</phone>
    <email>chensi.ouyang@va.gov</email>
  </overall_contact>
  <reference>
    <citation>Kavanaugh ML, Jerman J, Finer LB. Changes in Use of Long-Acting Reversible Contraceptive Methods Among U.S. Women, 2009-2012. Obstet Gynecol. 2015 Nov;126(5):917-27. doi: 10.1097/AOG.0000000000001094.</citation>
    <PMID>26444110</PMID>
  </reference>
  <reference>
    <citation>Asker C, Stokes-Lampard H, Beavan J, Wilson S. What is it about intrauterine devices that women find unacceptable? Factors that make women non-users: a qualitative study. J Fam Plann Reprod Health Care. 2006 Apr;32(2):89-94.</citation>
    <PMID>16824298</PMID>
  </reference>
  <reference>
    <citation>Hubacher D, Reyes V, Lillo S, Pierre-Louis B, Zepeda A, Chen PL, Croxatto H. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod. 2006 Jun;21(6):1467-72. Epub 2006 Feb 16.</citation>
    <PMID>16484309</PMID>
  </reference>
  <reference>
    <citation>Jensen HH, Blaabjerg J, Lyndrup J. [Prophylactic use of prostaglandin synthesis inhibitors in connection with IUD insertion]. Ugeskr Laeger. 1998 Nov 23;160(48):6958-61. Danish.</citation>
    <PMID>9846090</PMID>
  </reference>
  <reference>
    <citation>Chor J, Bregand-White J, Golobof A, Harwood B, Cowett A. Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine system insertion: a randomized controlled trial. Contraception. 2012 Jun;85(6):558-62. doi: 10.1016/j.contraception.2011.10.015. Epub 2011 Dec 15.</citation>
    <PMID>22176793</PMID>
  </reference>
  <reference>
    <citation>Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, Jensen JT; Post-Aspiration IUD Randomization (PAIR) Study Trial Group. Prophylactic ibuprofen does not improve pain with IUD insertion: a randomized trial. Contraception. 2015 Mar;91(3):193-7. doi: 10.1016/j.contraception.2014.11.012. Epub 2014 Nov 25.</citation>
    <PMID>25487172</PMID>
  </reference>
  <reference>
    <citation>Massey SE, Varady JC, Henzl MR. Pain relief with naproxen following insertion of an intrauterine device. J Reprod Med. 1974 Dec;13(6):226-31.</citation>
    <PMID>4612152</PMID>
  </reference>
  <reference>
    <citation>Ngo LL, Ward KK, Mody SK. Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial. Obstet Gynecol. 2015 Jul;126(1):29-36. doi: 10.1097/AOG.0000000000000912.</citation>
    <PMID>26241253</PMID>
  </reference>
  <reference>
    <citation>Ngo LL, Braaten KP, Eichen E, Fortin J, Maurer R, Goldberg AB. Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial. Obstet Gynecol. 2016 Dec;128(6):1306-1313.</citation>
    <PMID>27824753</PMID>
  </reference>
  <results_reference>
    <citation>Trussell J. Contraceptive failure in the United States. Contraception. 2011 May;83(5):397-404. doi: 10.1016/j.contraception.2011.01.021. Epub 2011 Mar 12. Review.</citation>
    <PMID>21477680</PMID>
  </results_reference>
  <results_reference>
    <citation>Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015 Apr 30;(4):CD002126. doi: 10.1002/14651858.CD002126.pub3. Review. Update in: Cochrane Database Syst Rev. 2020 Jun 12;6:CD002126.</citation>
    <PMID>25924648</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Orlando VA Medical Center</investigator_affiliation>
    <investigator_full_name>Chensi Ouyang</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>NSAID</keyword>
  <keyword>Intrauterine Devices</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

